ChemoCentryx

Traded on the St. Petersburg Stock Exchange
ChemoCentryx is an American biopharmaceutical company focused exclusively on discovering, developing and commercializing therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It was incorporated in 1996 and is headquartered in Mountain View, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

ChemoCentryx balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

ChemoCentryx cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

ChemoCentryx multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

ChemoCentryx profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
ChemoCentryx assets
ChemoCentryx cash flows

ChemoCentryx dividend policy

The company doesn't provide dividends
ChemoCentryx news
20.10.2022
Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.
Source: {source} pictogram investors.amgen.com
Pictogram next
04.08.2022
Amgen is buying ChemoCentryx for $3.7 billion, or $52 per share. The deal is scheduled to close in the fourth quarter of 2022.
Source: {source} pictogram investors.amgen.com
Pictogram next
06.05.2022
ChemoCentryx reported a GAAP loss of $38.608 million for the 3 months of 2022, up 29.9% from $29.711 million in the prior year. Revenue decreased 47.3% to $5.459 million from $10.353 million a year earlier.
Source: {source} pictogram ir.chemocentryx.com
Pictogram next
02.03.2022
Net income of ChemoCentryx under GAAP for 2021 was $131.755 million, up 2.4 times from $55.356 million in the previous year. Revenues halved to $32.224 million from $64.891 million a year earlier.
Source: {source} pictogram ir.chemocentryx.com
Pictogram next
All ChemoCentryx news
General information
Company nameChemoCentryx
Tags#biotechnology, #pharmacy, #cancer treatment
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address850 Maude Avenue Mountain View, CA 94043 United States
Mailing address850 Maude Avenue Mountain View, CA 94043 United States
Websiteir.chemocentryx.com